Paul W. Noble, MD, FCCP

Professor of Medicine
Chief, Division of Pulmonary, Allergy, and Critical Care Medicine
Duke University School of Medicine
Durham, North Carolina

Paul W. Noble, MD, FCCP, received his bachelor of arts degree from Haverford College in Pennsylvania, and his medical degree from New York University School of Medicine. He completed his medical residency and chief residency at the University of California, San Francisco Hospitals. He completed his pulmonary and critical care fellowships at the University of Colorado and the National Jewish Center in Denver, Colorado.

From 1992–1997 Dr. Noble was Assistant Professor at Johns Hopkins School of Medicine, where he established the Interstitial Lung Disease Clinic. He moved to the Yale University School of Medicine in 1997, where he became Professor of Medicine in 2004. He served as Director of the ILD Program until 2006, when he moved to Duke University as the Chief of the Division of Pulmonary, Allergy and Critical Care Medicine.

Dr. Noble is a physician scientist with an active research laboratory focused on elucidating the basic mechanisms of lung injury, inflammation, and fibrosis. His research laboratory is funded by the National Institutes of Health. He continues to have an active clinical practice in ILD. Dr. Noble is also involved in industry-sponsored clinical trials evaluating new therapies in IPF. He served as the Co-PI for protocol design for the CAPACITY trial evaluating the efficacy of pirfenidone in the treatment of IPF. He is on the Steering Committee for the INSPIRE trial evaluating the efficacy of interferon-gamma 1b in the treatment of IPF.

Dr. Noble is an elected member of the American Society of Clinical Investigation and the American Association of Physicians. He serves on the editorial boards for the American Journal of Respiratory Cell and Molecular Biology and the American Journal of Respiratory and Critical Care Medicine. Dr. Noble's research has been published in journals such as Science, Nature Medicine, the Journal of Clinical Investigation, and the New England Journal of Medicine.

Disclosure Statement

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a faculty member with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all faculty conflicts of interest prior to the release of this activity.

Paul W. Noble, MD, FCCP, has served as a consultant for Actelion, Boehringer Ingelheim, Gilead Sciences, Human Genome Sciences, InterMune, Johnson & Johnson, Novartis, and Stromedix. He has served as a speaker for InterMune.

Disclaimer
The opinions, recommendations, and guidelines expressed herein are those of the PILOT™ Steering Committee and other contributing faculty, and not necessarily those of The France Foundation or InterMune, who assume no responsibility or liability for the material that appears herein.